US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,288.98

-24.9406-1.90%

Number of Gainers:1

Number of Losers:19

Number of Flat:- -

PE:- -

High:1,317.52

Open:1,315.86

Low:1,288.03

Close:1,313.92

Loading ...

Solana on Its Way to Surpassing Ethereum, Top VC Says

These Companies Are Emerging as Potential Winners in Trump’s Trade War

Comstock Resources to List Shares on NYSE Texas

Gilead Sciences (GILD) Gets a Buy from Mizuho Securities

Johnson & Johnson Stock (JNJ) Perks Up as it Mulls $2.5B Purchase of Sonic Beam Cancer Fighting MedTech

European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%

Unstaked, Aptos, PEPE: Best Crypto for 2025 with Real Use

Moderna price target lowered to $70 from $78 at UBS

BRIEF-iBio Reports Fiscal Third Quarter 2025 Financial Results

Ibio Inc: Qtrly EPS From Cont Ops -$0.49

THOMSON REUTERS

Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13

Press Release: iBio Reports Fiscal Third Quarter 2025 Financial Results

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Astrazeneca Asthma Treatment Study Meets Primary Endpoints

MT Newswires Live

FACTBOX-European companies cut jobs in response to slowing economy

Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years

Simply Wall St.

BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma

Who’s backing who? Every newspaper’s pick for prime minister

The Sydney Morning Herald

Arvinas price target lowered to $16 from $32 at Barclays

Where Will Viking Therapeutics Be in 3 Years?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4568/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1288.9788,"timestamp":1747252799999,"preClose":1313.9193,"halted":0,"volume":122459245,"delay":0,"changeRate":-0.018982,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-24.940552,"latestTime":"05-14 16:00:00 EDT","open":1315.863,"high":1317.5182,"low":1288.0337,"amount":5312532338.460091,"amplitude":0.02244,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1747315800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.481117,"peRate":20.661892,"turnoverRate":0.007888,"increases":1,"decrements":19,"flats":0,"marketCap":1062734566215.5,"floatMarketCap":1044928346539},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1317.5182,"amplitude":0.02244,"preClose":1313.9193,"low":1288.0337,"pbRate":"3.481117","latestPrice":1288.9788,"volume":122459245,"delay":0,"open":1315.863,"prevYearClose":1274.8187,"prevWeekClose":1327.5806,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1351.4436,"twentyDayClose":1326.1057,"sixtyDayClose":1391.6339,"secType":"PLATE","market":"US","turnoverRate":0.007888,"peRate":20.661892,"marketCap":1062734566215.5,"floatMarketCap":1044928346539,"timestamp":1747252799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":1,"down":19,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532351973","title":"Solana on Its Way to Surpassing Ethereum, Top VC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2532351973","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532351973?lang=en_us&edition=fundamental","pubTime":"2025-05-03 12:55","pubTimestamp":1746248100,"startTime":"0","endTime":"0","summary":"Alliance DAO's Qiao Wang, seasoned cryptocurrency analyst and co-founder of Messari, shared the statistics of founders applying for funding to his fund in 2022-2025. Ethereum (ETH) is losing its domin","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/solana-on-its-way-to-surpassing-ethereum-top-vc-says","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BTC.USD.HKCC","09046","ETH","SUI","EZET","03009","03179","ATOM.AU","VC","BK4601","APT.USD.HKCC","APT.USD.CC","APT","BK4086","ATOM.USD.HKCC","BK4568","BK4228","LU0757428866.USD","SOL.AU","SOL.USD.HKCC","BK4124","SOL","ETHV","BK7105","BTC","ETH.USD.CC","09179","09009","AVAX.USD.HKCC","QETH","BK4519","IE00BZ199S13.USD","BK7083","APT.AU","ETH.USD.HKCC","LU1815336091.USD","03046","BK1611","BK4129","FETH","LDO.USD.HKCC","AVAX.USD.CC","BTC.AU","BK4215","BK4147","DOT.USD.CC","DOT.USD.HKCC","TRX","CETH","ATOM"],"gpt_icon":0},{"id":"2532382789","title":"These Companies Are Emerging as Potential Winners in Trump’s Trade War","url":"https://stock-news.laohu8.com/highlight/detail?id=2532382789","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532382789?lang=en_us&edition=fundamental","pubTime":"2025-05-03 09:30","pubTimestamp":1746235800,"startTime":"0","endTime":"0","summary":"This earnings season, companies in some sectors have started spelling out the potential financial impact of tariffs, while others have withdrawn their outlooks citing too much uncertaintyConsumer stap","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087625088.SGD","AAPL","IE00BSNM7G36.USD","SG9999015986.USD","JBLU","DAL","LUV","NWL","LU1868836591.USD","IE00BFSS7M15.SGD","GOOG","JNJ","LU0127658192.USD","LU2403377893.USD","LU1551013342.USD","BK4533","LU1732800096.USD","META","BK4568","CL","LU0724617625.USD","PEP","GOOGL","LU0265550359.USD","WHR","MRK","SG9999015952.SGD","NFLX","ABT","GM","GEHC","LU1267930813.SGD","IE00B775SV38.USD","KO","LU0310800965.SGD","LU0861579265.USD","LU0949170772.SGD","BK4503","AAL","LU2279689827.SGD","BK4500","LU0149725797.USD","LU2506952170.USD","LU1150488135.SGD","LU0949170426.SGD","PG","LU2506951958.HKD"],"gpt_icon":0},{"id":"2532741268","title":"Comstock Resources to List Shares on NYSE Texas","url":"https://stock-news.laohu8.com/highlight/detail?id=2532741268","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532741268?lang=en_us&edition=fundamental","pubTime":"2025-05-03 04:41","pubTimestamp":1746218460,"startTime":"0","endTime":"0","summary":"Natural gas producer Comstock Resources will list its shares on the NYSE Texas while retaining its primary listing on the New York Stock Exchange.Shares on both exchanges will continue trading under the symbol CRK, the company said Friday.The new fully electronic Texas exchange is the result of the NYSE reincorporating its Chicago exchange.Other companies with listings on both exchanges include Abbott Laboratories, Allstate, U.S. Steel and Whirlpool.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","IE00B4R5TH58.HKD","BK4504","SGXZ23171101.USD","BK4592","LU0234572021.USD","LU0266013472.USD","LU2089984988.USD","BK4585","LU1914381329.SGD","BK4566","LU2133065610.SGD","SG9999002232.USD","BK4581","IE00B2B36J28.USD","LU1989763690.USD","BK4568","BK4533","LU0122379950.USD","LU0170899867.USD","LU1057294990.SGD","LU2237957902.USD","BK4213","LU2237957811.SGD","SG9999004303.SGD","LU1721429741.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","CRK","LU2112291526.USD","LU1989763427.SGD","NYSE","IE0009355771.USD","LU0868494617.USD","LU1721429402.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","ABT","IE0002141913.USD","LU1691799644.USD","IE00BFTCPJ56.SGD","BK4588","BK4082","SG9999002224.SGD"],"gpt_icon":0},{"id":"2532878051","title":"Gilead Sciences (GILD) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2532878051","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532878051?lang=en_us&edition=fundamental","pubTime":"2025-05-03 02:15","pubTimestamp":1746209714,"startTime":"0","endTime":"0","summary":"In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price tar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/gilead-sciences-gild-gets-a-buy-from-mizuho-securities-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GILD","LU0058720904.USD","IE00BKVL7J92.USD","LU0234570918.USD","BK4207","LU0109394709.USD","LU1066051498.USD","IE00B19Z3B42.SGD","IE00BZ1G4Q59.USD","LU2087621335.USD","IE00BSNM7G36.USD","LU1066053197.SGD","LU1430594728.SGD","LU0889565916.HKD","BK4568","BK4588","BK4566","LU2089984988.USD","IE0002270589.USD","BK4585","IE00B19Z3581.USD","BK4532","LU1839511570.USD","BK4578","BK4139","MFG","BK4550","LU0320765992.SGD","LU1571399168.USD","LU1585245621.USD","IE00B3T34201.USD","LU0289739699.SGD","LU2468319806.SGD","BK4583","IE00B7SZLL34.SGD"],"gpt_icon":0},{"id":"2532822723","title":"Johnson & Johnson Stock (JNJ) Perks Up as it Mulls $2.5B Purchase of Sonic Beam Cancer Fighting MedTech","url":"https://stock-news.laohu8.com/highlight/detail?id=2532822723","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532822723?lang=en_us&edition=fundamental","pubTime":"2025-05-03 00:50","pubTimestamp":1746204629,"startTime":"0","endTime":"0","summary":"Shares in healthcare group Johnson & Johnson ($JNJ) were higher today on reports that it could be lining up a $2.5 billion bid for tumor zapping bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/johnson-johnson-stock-jnj-perks-up-as-it-mulls-2-5b-purchase-of-sonic-beam-cancer-fighting-medtech?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/johnson-johnson-stock-jnj-perks-up-as-it-mulls-2-5b-purchase-of-sonic-beam-cancer-fighting-medtech?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","IE00BSNM7G36.USD","LU1261432733.SGD","LU2602419157.SGD","LU1674673428.USD","IE00BBT3K403.USD","LU0795875086.SGD","LU1929549753.HKD","LU1059921491.USD","IE00BJJMRZ35.SGD","LU0640476718.USD","LU2129689514.USD","LU1066051225.USD","LU1244550577.SGD","LU1506573853.SGD","LU1066051498.USD","LU1430594728.SGD","IE0002270589.USD","IE0034235303.USD","LU1221951129.SGD","SG9999001440.SGD","LU1267930813.SGD","LU1162221912.USD","LU1196500208.SGD","IE00BGHQF631.EUR","LU1066051811.HKD","LU0792757196.USD","LU0345769128.USD","JNJ","IE00BDGV0183.EUR","IE00B7SZLL34.SGD","LU1914381329.SGD","LU1894683348.USD","LU2468319806.SGD","IE00B2B36J28.USD","LU1674673691.USD","IE00BVYPNW00.USD","LU2133065610.SGD","BK4568","LU0058720904.USD","IE00B1BXHZ80.USD","IE00BLSP4452.SGD","LU1244550221.USD","LU1732800096.USD","LU0203345920.USD","LU0889566641.SGD","LU1778281490.HKD","LU0882574055.USD","BK4581","BK4585"],"gpt_icon":0},{"id":"2532827248","title":"European Equities Close Sharply Higher in Friday Trading; Eurozone Inflation Unchanged at 2.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532827248","media":"MT Newswires","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532827248?lang=en_us&edition=fundamental","pubTime":"2025-05-03 00:09","pubTimestamp":1746202161,"startTime":"0","endTime":"0","summary":"The European stock markets closed sharply higher in Friday trading as the Stoxx Europe 600 climbed 1.68%, Germany's DAX surged 2.49%, the FTSE 100 rose 1.17%, France's CAC 40 increased 2.33%, and the Swiss Market Index was up 1.13%.Eurozone annual inflation is expected to be 2.2% in April, which is unchanged from March, according to a flash estimate from Eurostat, the statistical office of the European Union. Estonia had the highest estimated annual inflation rate at 4.4%, while France had the lowest rate at 0.8%.Eurostat also reported that the eurozone seasonally adjusted unemployment rate was 6.2% in March, unchanged from February, and down from 6.5% a year earlier. And in the EU, the unemployment rate was 5.8% in March, which was also unchanged from February and down from 6.0% a year earlier.The HCOB Eurozone Manufacturing PMI, which gauges the health of eurozone factories compiled by S&P Global, rose for the fourth straight month in April, registering a 32-month high of 49.0, up fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/european-equities-close-sharply-higher-160921735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU2236285917.USD","AZN","BK4585","LU0320765992.SGD","LU1829250122.USD","LU0889565916.HKD","BK4007","LU2417539215.USD","LU2456880835.USD","BK4568","LU2462157665.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2532823328","title":"Unstaked, Aptos, PEPE: Best Crypto for 2025 with Real Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2532823328","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532823328?lang=en_us&edition=fundamental","pubTime":"2025-05-02 22:39","pubTimestamp":1746196792,"startTime":"0","endTime":"0","summary":"Beyond Hype and Price Surges: Unstaked Delivers Sustainable 24/7 Brand Growth That PEPE and Aptos Can't Match!Around-the-clock visibility has become essential for digital creators and entrepreneurs aiming to stay competitive. The ability to engage consistently isn't just a perk; it’s a core requirement in a saturated online space.Aptos  garners attention through its technical strengths and optimistic price predictions, while PEPE  captures early momentum with its $8 million presale. However, both fall short of solving the ongoing demand for active, real-time digital presence.Unstaked  shifts focus from speculation to functionality. With AI agents that autonomously manage engagement across platforms, the presale introduces a crypto asset rooted in practical use. For those seeking the best crypto for 2025, Unstaked delivers utility built for sustained visibility.Each Unstaked agent can be fully customized with tone, behavior, and specific brand goals. This allows them to function as auto","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6814d938b6c2463501b21518/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["TON.USD.HKCC","APT.USD.CC","BK4568","TON.USD.CC","APT","BK4086","APT.USD.HKCC"],"gpt_icon":0},{"id":"2532984107","title":"Moderna price target lowered to $70 from $78 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2532984107","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532984107?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:36","pubTimestamp":1746193015,"startTime":"0","endTime":"0","summary":"UBS lowered the firm’s price target on Moderna (MRNA) to $70 from $78 and keeps a Buy rating on the shares. While there remain “uncertainties” in v...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-price-target-lowered-to-70-from-78-at-ubs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-price-target-lowered-to-70-from-78-at-ubs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4548","BK4533","BK4532","BK4501","BK4534","BK4551","BK4588","MRNA","BK4568","BK4585","BK4139"],"gpt_icon":0},{"id":"2532419108","title":"BRIEF-iBio Reports Fiscal Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532419108","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532419108?lang=en_us&edition=fundamental","pubTime":"2025-05-02 21:31","pubTimestamp":1746192694,"startTime":"0","endTime":"0","summary":"BRIEF-iBio Reports Fiscal Third Quarter 2025 Financial ResultsMay 2 (Reuters) - iBio Inc IBIO.O:IBIO REPORTS FISCAL THIRD QUARTER 2025 FINANCIAL RESULTSIBIO INC:  QTRLY EPS FROM CONTINUING OPERATIONS ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA1L8YL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBIO","BK4139","BK4568"],"gpt_icon":0},{"id":"2532784813","title":"Ibio Inc:  Qtrly EPS From Cont Ops -$0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2532784813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532784813?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nTUA1L8YL1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBIO","BK4139","BK4568"],"gpt_icon":0},{"id":"2532884878","title":"Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2532884878","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532884878?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May 02, 2025  -- Vaxart, Inc. today announced it will provide a business update and report financial results for the first quarter ended March 31, 2025, after the market close on Tuesday, May 13, 2025. The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m. ET.The conference call can be accessed using the following information:. Webcast: Click hereDate: Tuesday, May 13, 2025 – 4:30 p.m. ETDomestic:  407-0832International:  689-8433Conference ID: 13753354. This press release was published by a CLEAR Verified individual.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaxart-host-first-quarter-2025-120000093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HST","BK4588","BK4139","VXRT","BK4585","BK4218","BK4568","BK4181"],"gpt_icon":0},{"id":"2532485688","title":"Press Release: iBio Reports Fiscal Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532485688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532485688?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, May 02, 2025  -- iBio, Inc. , today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress.\"During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of IBIO-600 in 2026,\" said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. \"At the same time, we made significant strides in our pipeline, with promising non-human primate data for IBIO-600 and the in-licensing of a first-in-class Activin E antibody, two antibodies we truly believe are bringing us closer to fulfilling our mission of delivering transformative therapies to patients suffering from cardiometabolic diseases and obesity.\". Fiscal Third Quarter 2025 & Recent Corporate Updates:.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","IBIO","NQmain"],"gpt_icon":0},{"id":"2532482118","title":"Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2532482118","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532482118?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., May 02, 2025  -- Ocugen, Inc.  , a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025.Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:. Dial-in Numbers:  715-9871 for U.S. callers and  307-1963 for international callersConference ID: 1773288Webcast: Available on theeventssection of the Ocugeninvestor site. A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugeninvestor site.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ocugen-host-conference-call-friday-120000294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HST","BK4585","ET","BK4181","BK4561","BK4144","BK4139","BK4218","BK4581","BK4568","BK4590","BK4588","OCGN","BK4563"],"gpt_icon":0},{"id":"2532810122","title":"Astrazeneca Asthma Treatment Study Meets Primary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810122","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810122?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:42","pubTimestamp":1746186167,"startTime":"0","endTime":"0","summary":"Astrazeneca (AZN) said Friday that its fixed-dose triple-combination therapy Breztri Aerosphere met all primary endpoints in a phase 3 trial to treat asthma.The British pharmaceutical company said the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","LU0109394709.USD","LU2462157665.USD","AZN","LU2236285917.USD","LU2456880835.USD","BK4588","BK4568","BK4007","BK4585","LU1829250122.USD","LU0889565916.HKD","LU2417539215.USD"],"gpt_icon":0},{"id":"2532810559","title":"FACTBOX-European companies cut jobs in response to slowing economy","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810559","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810559?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:39","pubTimestamp":1746185959,"startTime":"0","endTime":"0","summary":"FACTBOX-European companies cut jobs in response to slowing economyAdds LVMH, STMicro, updates Volkswagen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250502:nL8N3RA0YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","BNTX","BK4139","BK4585","BK4568","BK4535","BK4548"],"gpt_icon":0},{"id":"2532817591","title":"Investors in Abbott Laboratories (NYSE:ABT) have seen notable returns of 52% over the past five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2532817591","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532817591?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183617,"startTime":"0","endTime":"0","summary":"The main point of investing for the long term is to make money. Better yet, you'd like to see the share price move up more than the market average. But Abbott Laboratories  has fallen short of that second goal, with a share price rise of 39% over five years, which is below the market return. On a brighter note, more newer shareholders are probably rather content with the 24% share price gain over twelve months.With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share  with the share price movement.During five years of share price growth, Abbott Laboratories achieved compound earnings per share  growth of 31% per year","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/investors-abbott-laboratories-nyse-abt-110017872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0009355771.USD","BK4585","LU1023059063.AUD","SG9999002232.USD","SGXZ23171101.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4568","LU0170899867.USD","LU2112291526.USD","IE00B4R5TH58.HKD","LU2237957902.USD","SG9999004303.SGD","BK4211","BK4581","ISBC","LU1691799644.USD","LU1989763427.SGD","LU1989763690.USD","SG9999002224.SGD","LU0234572021.USD","BK4588","LU1061106388.HKD","LU0122379950.USD","LU2133065610.SGD","LU0266013472.USD","LU2089984988.USD","LU2468319806.SGD","IE00B2B36J28.USD","LU1914381329.SGD","BK4566","LU0868494617.USD","LU1057294990.SGD","BK4082","IE0002141913.USD","BK4504","NYSE","ABT","LU1721429741.USD","IE00BJJMRZ35.SGD","LU1721429402.USD","BK4592","LU2237957811.SGD","BK4533"],"gpt_icon":0},{"id":"2532810675","title":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2532810675","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532810675?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:00","pubTimestamp":1746183600,"startTime":"0","endTime":"0","summary":"KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI as a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRI versus maintenance treatment with ICS/LABA in adults and adolescents with uncontrolled asthma.1,2. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: \"We are excited by the positive results from the KALOS and LOGOS trials, which demonstrate that BREZTRI could help improve the lives of the millions of patients living with asthma. These asthma data build on the well-established profile of BREZTRI in COPD, and we look forward to sharing with regulatory authorities to bring this important medicine to a wider group of patients.\". There were no new safety or tolerability signals identified for BREZTRI in KALOS or LOGOS.Full results from the two Phase III trials will be shared with regulatory authorities and presented at an upcoming medical meeting.BREZTRI is an inhaled tri","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/breztri-met-primary-endpoints-kalos-110000396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU0889565916.HKD","LU2417539215.USD","BK4568","LU0109394709.USD","LU0320765992.SGD","LU1829250122.USD","LU2236285917.USD","CDC","BK4134","BK4007","III","LU2462157665.USD","AZN","BK4585","LU2456880835.USD"],"gpt_icon":0},{"id":"2532501819","title":"Who’s backing who? Every newspaper’s pick for prime minister","url":"https://stock-news.laohu8.com/highlight/detail?id=2532501819","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532501819?lang=en_us&edition=fundamental","pubTime":"2025-05-02 17:00","pubTimestamp":1746176400,"startTime":"0","endTime":"0","summary":"It’s tradition for Australia’s biggest newspapers to editorially endorse a party in print and online the day before Australians head to the polls.On Friday, a slim majority of newspapers, led by News ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/who-s-backing-who-every-newspaper-s-pick-for-prime-minister-20250501-p5lvup.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["ABT","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","BK4504","IE00BJJMRZ35.SGD","BK4581","LU2112291526.USD","LU2089984988.USD","LU1691799644.USD","LU0868494617.USD","LU1721429741.USD","XKO.AU","LU2133065610.SGD","XJO.AU","BK4568","IE00BFTCPJ56.SGD","LU1061106388.HKD","LU2468319806.SGD","BK4566","LU2237957811.SGD","LU0266013472.USD","LU0234572021.USD","LU2237957902.USD","LU0170899867.USD","BK4588","IE0009355771.USD","LU1989763427.SGD","SG9999002224.SGD","XAO.AU","IE00B2B36J28.USD","BK4585","IE0002141913.USD","LU1914381329.SGD","LU1721429402.USD","LU1989763690.USD","SG9999002232.USD","BK4533","BK4082","LU0122379950.USD","SG9999004303.SGD","SGXZ23171101.USD","BK4592","LU1057294990.SGD","LU1023059063.AUD"],"gpt_icon":0},{"id":"2532890674","title":"Arvinas price target lowered to $16 from $32 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2532890674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532890674?lang=en_us&edition=fundamental","pubTime":"2025-05-02 16:50","pubTimestamp":1746175849,"startTime":"0","endTime":"0","summary":"Barclays lowered the firm’s price target on Arvinas (ARVN) to $16 from $32 and keeps an Overweight rating on the shares. The firm says Pfizer reduc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arvinas-price-target-lowered-to-16-from-32-at-barclays?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arvinas-price-target-lowered-to-16-from-32-at-barclays?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1023059063.AUD","LU0225771236.USD","ARVN","BK4599","IE0002270589.USD","LU0868494617.USD","LU1066053197.SGD","BK4581","LU1894683264.USD","IE00B19Z3B42.SGD","BK4585","BK4588","IE00B19Z3581.USD","BK4533","LU0306807586.USD","LU1057294990.SGD","LU1066051498.USD","LU0122379950.USD","LU0306806265.USD","BK4534","SG9999001176.SGD","LU0234572021.USD","LU0985481810.HKD","LU0321505439.SGD","IE00BBT3K403.USD","LU0456855351.SGD","LU0225284248.USD","SG9999002224.SGD","SG9999003800.SGD","SG9999001176.USD","LU0170899867.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","LU0058720904.USD","LU1883839398.USD","LU0289739699.SGD","BK4007","IE00BLSP4452.SGD","SG9999011175.SGD","LU1894683348.USD","LU0321505868.SGD","SG9999013999.USD","SG9999002232.USD","BK4568","BK4550","BK4592","IE00BLSP4239.USD"],"gpt_icon":0},{"id":"2532894454","title":"Where Will Viking Therapeutics Be in 3 Years?","url":"https://stock-news.laohu8.com/highlight/detail?id=2532894454","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532894454?lang=en_us&edition=fundamental","pubTime":"2025-05-02 16:20","pubTimestamp":1746174000,"startTime":"0","endTime":"0","summary":"Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/05/02/where-will-viking-therapeutics-be-in-3-years/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4550","BK4588","BK4581","SG9999002224.SGD","LU0321505439.SGD","SG9999013999.USD","SGXZ57979304.SGD","LU0225771236.USD","BK4568","LU0289739699.SGD","IE00B19Z3581.USD","LU0170899867.USD","LU0225284248.USD","LU1883839398.USD","IE0002270589.USD","IE00B19Z3B42.SGD","LU0058720904.USD","LU1023059063.AUD","BK4534","LU0456855351.SGD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0868494617.USD","LU1894683348.USD","LU0321505868.SGD","SG9999001176.USD","LU0306806265.USD","LU1066051498.USD","BK4592","IE00BBT3K403.USD","BK4533","LU0306807586.USD","IE000M9KFDE8.USD","LU0985481810.HKD","SG9999002232.USD","LU1894683264.USD","SG9999011175.SGD","BK4139","VKTX","BK4585","BK4007","LU0234572021.USD","SG9999001176.SGD","SG9999003800.SGD","LU1057294990.SGD","LU0122379950.USD","BK4599","IE00BLSP4239.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":12,"pageCount":10,"totalSize":231,"code":"91000000","status":"200"}]}}